Antibody-based immunotherapeutics and use of convalescent plasma to counter COVID-19: advances and prospects

References

• Gupta AK, Jneid H, Addison D, et al. Current perspectives on Coronavirus 2019 (COVID-19) and cardiovascular disease: A white paper by the JAHA editors [published online ahead of print, 2020 Apr 29]. J Am Heart Assoc. 2020;e017013. DOI:10.1161/JAHA.120.017013.
   PubMed Web of Science ®Google Scholar
• WHO. 2020. [cited 2020 May 18]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports
   Google Scholar
• Dhama K, Sharun K, Tiwari R, et al. Coronavirus Disease 2019 – COVID-19. Clin Microbiol Rev. 2020 Jun 24;33(4):e00028–20.
   PubMed Web of Science ®Google Scholar
• Harapan H, Itoh N, Yufika A, et al. Coronavirus disease 2019 (COVID-19): A literature review. J Infect Public Health. 2020;13:667–673.
   PubMed Web of Science ®Google Scholar
• Dhama K, Patel SK, Sharun K, et al. Jumping the species barrier, lessons from SARS and MERS, its zoonotic spillover, transmission to humans, preventive and control measures and recent developments to counter this pandemic virus. Preprints. 2020;2020040011. DOI:10.20944/preprints202004.0011.v1.
   Google Scholar
• Rodriguez-Morales AJ, Cardona-Ospina JA, Gutierrez-Ocampo E, et al. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. Travel Med Infect Dis. 2020;34:101623.
   PubMed Web of Science ®Google Scholar
• Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565‐574.
   Web of Science ®Google Scholar
• Malik YS, Sircar S, Bhat S, et al. Emerging novel coronavirus (2019-nCoV)-current scenario, evolutionary perspective based on genome analysis and recent developments. Vet Q. 2020;40(1):68–76.
   PubMed Web of Science ®Google Scholar
• Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270‐273.
   Web of Science ®Google Scholar
• Ye Q, Wang B, Mao J, et al. Epidemiological analysis of COVID-19 and practical experience from China [published online ahead of print, 2020 Apr 1]. J Med Virol. 2020. DOI:10.1002/jmv.25813.
   Web of Science ®Google Scholar
• Zhang T, Wu Q, Zhang Z. Probable pangolin origin of SARS-CoV-2 associated with the COVID-19 outbreak [published correction appears in Curr Biol. 2020;30(8):1578]. Curr Biol. 2020;30(7):1346–1351.e2.
   PubMed Web of Science ®Google Scholar
• Petrosillo N, Viceconte G, Ergonul O, et al. COVID-19, SARS and MERS: are they closely related? [published online ahead of print, 2020 Mar 28]. Clin Microbiol Infect. 2020;S1198-743X(20)30171–3. DOI:10.1016/j.cmi.2020.03.026.
   Web of Science ®Google Scholar
• Kupferschmidt K, Cohen J. Race to find COVID-19 treatments accelerates. Science. 2020;367(6485):1412‐1413.
   Web of Science ®Google Scholar
• Li Z, Ge J, Yang M, et al. Vicarious traumatization in the general public, members, and non-members of medical teams aiding in COVID-19 control. Brain Behav Immun. 2020. DOI:10.1016/j.bbi.2020.03.007. S0889-1591(20)30309-3.
   Web of Science ®Google Scholar
• Dhama K, Sharun K, Tiwari R, et al. COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics. Hum Vaccin Immunother. 2020:1–7. DOI: 10.1080/21645515.2020.1735227.
   PubMed Web of Science ®Google Scholar
• Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–513.
   PubMed Web of Science ®Google Scholar
• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506.
   PubMed Web of Science ®Google Scholar
• Tobaiqy M, Qashqary M, Al-Dahery S, et al. Therapeutic management of COVID-19 patients: a systematic review. Infection Prevention in Practice. 2020;2(3):100061.
   Google Scholar
• Esposito S, Noviello S, Pagliano P. Update on treatment of COVID-19: ongoing studies between promising and disappointing results. Infez Med. 2020;28(2):198–211.
   PubMedGoogle Scholar
• Atluri S, Manchikanti L, Hirsch JA. Expanded umbilical cord mesenchymal stem cells (UC-MSCs) as a therapeutic strategy in managing critically Ill COVID-19 patients: the case for compassionate use. Pain Physician. 2020;23(2):E71‐E83.
   Web of Science ®Google Scholar
• Jin YH, Cai L, Cheng ZS, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Military Med Res. 2020;7:4.
   PubMed Web of Science ®Google Scholar
• Casadevall A, Pirofski LA. The convalescent sera option for containing COVID-19. J Clin Invest. 2020;130(4):1545–1548.
   PubMed Web of Science ®Google Scholar
• Ahn JY, Sohn Y, Lee SH, et al. Use of convalescent plasma therapy in two COVID-19 patients with acute respiratory distress syndrome in Korea. J Korean Med Sci. 2020;35(14):e149.
   PubMed Web of Science ®Google Scholar
• Chen L, Xiong J, Bao L, et al. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis. 2020;20(4):398–400.
   PubMed Web of Science ®Google Scholar
• Kumar GV, Jeyanthi V, Ramakrishnan S. A short review on antibody therapy for COVID-19. New Microbes New Infect. 2020;35:100682.
   PubMed Web of Science ®Google Scholar
• Teixeira da Silva JA. Convalescent plasma: A possible treatment of COVID-19 in India. Med J Armed Forces India. 2020;76(2):236–237.
   PubMedGoogle Scholar
• Shanmugaraj B, Siriwattananon K, Wangkanont K, et al. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19). Asian Pac J Allergy Immunol. 2020;38(1):10–18.
   PubMed Web of Science ®Google Scholar
• Kirchdoerfer RN, Cottrell CA, Wang N, et al. Pre-fusion structure of a human coronavirus spike protein. Nature. 2016;531:118–121.
   PubMed Web of Science ®Google Scholar
• Cheng H, Wang Y, Wang GQ. Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19 [published online ahead of print, 2020 Mar 27]. J Med Virol. 2020. DOI:10.1002/jmv.25785
   Web of Science ®Google Scholar
• Bloch EM, Shoham S, Casadevall A, et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest. 2020;138745. DOI:10.1172/JCI138745.
   PubMed Web of Science ®Google Scholar
• Keith P, Day M, Perkins L, et al. A novel treatment approach to the novel coronavirus: an argument for the use of therapeutic plasma exchange for fulminant COVID-19. Crit Care. 2020;24(1):128.
   PubMed Web of Science ®Google Scholar
• Ye M, Fu D, Ren Y, et al. Treatment with convalescent plasma for COVID-19 patients in Wuhan, China. J Med Virol. 2020. doi:10.1002/jmv.25882.
   Web of Science ®Google Scholar
• Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A. 2020;202004168. DOI:10.1073/pnas.2004168117.
   Web of Science ®Google Scholar
• Tiberghien P, De Lambalerie X, Morel P, et al. Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how. Vox Sang. 2020. DOI:10.1111/vox.12926.
   Web of Science ®Google Scholar
• Shen C, Wang Z, Zhao F, et al. Treatment of 5 critically Ill patients with COVID-19 with convalescent plasma. JAMA. 2020;e204783. DOI:10.1001/jama.2020.4783.
   Web of Science ®Google Scholar
• Hartman WR, Hess AS, Connor J. Persistent viral RNA shedding after COVID-19 symptom resolution in older convalescent plasma donors. Transfusion. 2020. DOI:10.1111/trf.15927
   Web of Science ®Google Scholar
• Cheng Y, Wong R, Soo YOY, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2005;24(1):44–46.
   PubMed Web of Science ®Google Scholar
• Zhang B, Liu S, Tan T, et al. Treatment with convalescent plasma for critically ill patients with severe acute respiratory syndrome coronavirus 2 infection. Chest. 2020;158(1):e9-e13. S0012-3692(20)30571-7.
   PubMed Web of Science ®Google Scholar
• Lindholm PF, Ramsey G, Kwaan HC. passive immunity for coronavirus disease 2019: a commentary on therapeutic aspects including convalescent plasma. Semin Thromb Hemost. 2020. DOI:10.1055/s-0040-1712157
   PubMed Web of Science ®Google Scholar
• Nurtop E, Villarroel PMS, Pastorino B, et al. Correction to: combination of ELISA screening and seroneutralisation tests to expedite Zika virus seroprevalence studies. Virol J. 2019;16(1):12.
   PubMedGoogle Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): national Library of Medicine (US). 2020 Mar 12 – identifier NCT04261426, the efficacy of intravenous immunoglobulin therapy for severe 2019-nCoV infected pneumonia. Available from: https://clinicaltrials.gov/ct2/show/NCT04261426
   Google Scholar
• Rojas M, Rodríguez Y, Monsalve DM, et al. Convalescent plasma in Covid-19: possible mechanisms of action. Autoimmun Rev. 2020;19(7):102554.
   PubMed Web of Science ®Google Scholar
• Lünemann JD, Nimmerjahn F, Dalakas MC. Intravenous immunoglobulin in neurology-mode of action and clinical efficacy. Nat Rev Neurol. 2015;11(2):80–89.
   PubMed Web of Science ®Google Scholar
• Zhai P, Ding Y, Wu X, et al. The epidemiology, diagnosis and treatment of COVID-19 [published online ahead of print, 2020 Mar 28]. Int J Antimicrob Agents. 2020;55(5):105955.
   PubMed Web of Science ®Google Scholar
• FDA. 2020. FDA.: investigational COVID-19 convalescent plasma - emergency INDs. Food and Drug Administration 2020. Silver Spring, MD.
   Google Scholar
• Joyner MJ, Wright RS, Fairweather D, et al. Early safety indicators of COVID-19 convalescent plasma in 5,000 patients. J Clin Invest. 2020;140200. doi:10.1172/JCI140200.
   PubMed Web of Science ®Google Scholar
• Xia X, Li K, Wu L, et al. Improved clinical symptoms and mortality on severe/critical COVID-19 patients utilizing convalescent plasma transfusion. Blood. 2020 Jun 23. DOI:10.1182/blood.2020007079. blood.2020007079.
   PubMed Web of Science ®Google Scholar
• Olivares-Gazca JC, Priesca-Marín JM, Ojeda-Laguna M, et al. Infusion of convalescent plasma is associated with clinical improvement in critically ill patients with COVID-19: A pilot study. Rev Invest Clin. 2020;72(3):159–164.
   PubMedGoogle Scholar
• Hartman W, Hess AS, Connor JP. Hospitalized COVID-19 patients treated with convalescent plasma in a mid-size city in the midwest. medRxiv [Preprint]. [cited 2020 Jun 22]. 2020.06.19.20135830. DOI:10.1101/2020.06.19.20135830.
   Google Scholar
• Li L, Zhang W, Hu Y, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA. 2020Jun;3:e2010044.
   Google Scholar
• Casadevall A, Joyner MJ, Pirofski LA. A randomized trial of convalescent plasma for COVID-19-potentially hopeful signals. JAMA. 2020 Jun 3. DOI:10.1001/jama.2020.10218.
   PubMed Web of Science ®Google Scholar
• Zhou G, Zhao Q. Perspectives on therapeutic neutralizing antibodies against the novel coronavirus SARS-CoV-2. Int J Biol Sci. 2020;16(10):1718–1723.
   PubMed Web of Science ®Google Scholar
• Guo L, Ren L, Yang S, et al. Profiling early humoral response to diagnose novel coronavirus disease (COVID-19). Clin Infect Dis. 2020;ciaa310. DOI:10.1093/cid/ciaa310
   Web of Science ®Google Scholar
• Okba NMA, Müller MA, Li W, et al. Severe acute respiratory syndrome Coronavirus 2-specific antibody responses in coronavirus disease 2019 patients. Emerg Infect Dis. 2020;26:7.
   Web of Science ®Google Scholar
• To KK, Tsang OT, Leung WS, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis. 2020;20(5):565–574.
   PubMed Web of Science ®Google Scholar
• Zhao J, Yuan Q, Wang H, et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis. 2020;ciaa344. DOI:10.1093/cid/ciaa344
   PubMed Web of Science ®Google Scholar
• Alpaugh K, von Mehren M. Monoclonal antibodies in cancer treatment: a review of recent progress. BioDrugs. 1999;12(3):209–236.
   PubMed Web of Science ®Google Scholar
• Oei AL, Sweep FC, Thomas CM, et al. The use of monoclonal antibodies for the treatment of epithelial ovarian cancer (review). Int J Oncol. 2008;32:1145–1157.
   PubMed Web of Science ®Google Scholar
• Agustoni F, Suda K, Yu H, et al. EGFR-directed monoclonal antibodies in combination with chemotherapy for treatment of non-small-cell lung cancer: an updated review of clinical trials and new perspectives in biomarkers analysis. Cancer Treat Rev. 2019;72:15–27.
   PubMed Web of Science ®Google Scholar
• Lu RM, Hwang YC, Liu IJ, et al. Development of therapeutic antibodies for the treatment of diseases. J Biomed Sci. 2020;27(1):1.
   PubMed Web of Science ®Google Scholar
• Chen X, Li R, Pan Z, et al. Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor. Cell Mol Immunol. 2020;17(6):647–649.
   Web of Science ®Google Scholar
• Tai W, He L, Zhang X, et al. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell Mol Immunol. 2020;17(6):613–620.
   PubMed Web of Science ®Google Scholar
• Jiang S, Hillyer C, Du L. Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses. Trends Immunol. 2020;41:5,355–359.
   PubMed Web of Science ®Google Scholar
• Tian X, Li C, Huang A, et al. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg Microbes Infect. 2020;9(1):382–385.
   PubMed Web of Science ®Google Scholar
• Duan J, Yan X, Guo X, et al. A human SARS-CoV neutralizing antibody against epitope on S2 protein. Biochem Biophys Res Commun. 2005;333:186–193.
   PubMed Web of Science ®Google Scholar
• Elshabrawy HA, Coughlin MM, Baker SC, et al. Human monoclonal antibodies against highly conserved HR1 and HR2 domains of the SARS-CoVspike protein are more broadly neutralizing. PLoS One. 2012;7:e50366.
   PubMed Web of Science ®Google Scholar
• Ou X, Liu Y, Lei X, et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun. 2020;11(1):1620.
   PubMed Web of Science ®Google Scholar
• Wang C, Li W, Dubravka D, et al. A human monoclonal antibody blocking SARS-CoV-2 infection. bioRxiv. 2020. DOI:10.1101/2020.03.11.987958.
   Google Scholar
• Jun Lan JG, Yu J, Shan S, et al. Crystal structure of the 2019-nCoV spike receptor-binding domain bound with the ACE2 receptor. bioRxiv. 2020. DOI:10.1101/2020.02.19.956235. 2020.02.19.956235.
   Google Scholar
• Yan R, Zhang Y, Li Y, et al. Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2. Science. 2020;367:1444–1448.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): national Library of Medicine (US). 2020 Mar 12 – identifier NCT04275414, Bevacizumab in severe or critical patients with Covid-19 pneumonia (BEST-CP). Available from: https://clinicaltrials.gov/ct2/show/NCT04275414?term=NCT04275414&draw=2&rank=1
   Google Scholar
• Cao X. COVID-19: immunopathology and its implications for therapy. Nat Rev Immunol. 2020;20(5):269–270.
   PubMed Web of Science ®Google Scholar
• Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science. 2020;01(may):473–474.
   Google Scholar
• Zhang C, Wu Z, Li JW, et al. The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality. Int J Antimicrob Agents. 2020;55(5):105954.
   PubMed Web of Science ®Google Scholar
• Gritti G, Raimondi F, Ripamonti D, et al. Use of siltuximab in patients with COVID-19 pneumonia requiring ventilatory support medRxiv. 2020 [cited 2004 Jan 4]:8561. DOI:10.1101/2020.04.01.20048561.
   Google Scholar
• Liu T, Zhang J, Yang Y, et al. The potential role of IL-6 in monitoring coronavirus disease 2019. 2020. SSRN. 3548761. DOI:10.2139/ssrn.3548761.
   Google Scholar
• Luo P, Liu Y, Qiu L, et al. Tocilizumab treatment in COVID-19: A single center experience. J Med Virol. 2020;92(7):814–818.
   Web of Science ®Google Scholar
• Rilinger J, Kern WV, Duerschmied D, et al. A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial. Version 2. Trials. 2020;21(1):470.
   PubMedGoogle Scholar
• Novi G, Mikulska M, Briano F, et al. COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role? MultSclerRelatDisord. 2020;42:102120.
   Google Scholar
• Diurno F, Numis FG, Porta G, et al. Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience. Eur Rev Med Pharmacol Sci. 2020;24(7):4040–4047.
   PubMed Web of Science ®Google Scholar
• Zost SJ, Gilchuk P, Case JB, et al. Potently neutralizing human antibodies that block SARS-CoV-2 receptor binding and protect animals. bioRxiv [Preprint]. 2020;2020(5):22.111005.
   Google Scholar
• [cited 2020 May 18]. Available from: https://www.prnewswire.com/news-releases/regeneron-begins-first-clinical-trials-of-anti-viral-antibody-cocktail-regn-cov2-for-the-treatment-and-prevention-of-covid-19-301074103.html.
   Google Scholar
• [cited 2020 May 18]. Available from:https://www.pbiforum.net/mag/featured/lily-begins-phase-1-study-for-second-potential-covid-19-antibody-treatment/.
   Google Scholar
• [cited 2020 May 18]. Available from:https://www.biospectrumasia.com/news/26/16091/tychan-to-begin-first-clinical-trials-for-monoclonal-antibody-against-covid-19.html.
   Google Scholar
• Pinto D, Park Y-J, Beltramello M, et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature. 2020;583(7815):290–295.
   PubMed Web of Science ®Google Scholar
• AminJafari A, Ghasemi S. The possible of immunotherapy for COVID-19: A systematic review. Int Immunopharmacol. 2020;83:106455.
   PubMed Web of Science ®Google Scholar
• Kruse RL. Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China. F1000Res. 2020;9:72.
   PubMedGoogle Scholar
• Cao W, Liu X, Bai T, et al. High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease 2019. Open Forum Infect Dis. 2020;7(3):ofaa102.
   PubMed Web of Science ®Google Scholar
• Jawhara S. Could Intravenous immunoglobulin collected from recovered coronavirus patients protect against COVID-19 and strengthen the immune system of new patients? Int J Mol Sci. 2020;21(7):E2272.
   PubMed Web of Science ®Google Scholar
• Harapan H, Itoh N, Yufika A, et al. Coronavirus disease 2019 (COVID-19): A literature review. J Infect Public Health. 2020;13(5):667–673.
   PubMed Web of Science ®Google Scholar
• Keam S, Megawati D, Patel S, et al. Immunopathology and immunotherapeutic strategies in SARS-CoV-2 infection. Rev Medical Virol. 2020. doi:10.1002/rmv.2123
   PubMed Web of Science ®Google Scholar
• Shi H, Zhou C, He P, et al. Successful treatment of plasma exchange followed by intravenous immunogloblin in a critically ill patient with 2019 novel coronavirus infection. Int J Antimicrob Agents. 2020;105974. DOI:10.1016/j.ijantimicag.2020.105974.
   PubMedGoogle Scholar
• Daneshpazhooh M, Soori T, Isazade A, et al. Mucous membrane pemphigoid and COVID-19 treated with high-dose intravenous immunoglobulins: a case-report. J Dermatolog Treat. 2020;1–6. DOI:10.1080/09546634.2020.1764472.
   Web of Science ®Google Scholar
• Lin L, Lu L, Cao W, et al. Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia. Emerg Microbes Infect. 2020;9(1):727–732.
   PubMed Web of Science ®Google Scholar
• Fu Y, Cheng Y, Wu Y. Understanding SARS-CoV-2-mediated inflammatory responses: from mechanisms to potential therapeutic tools. Virol Sin. 2020;35(3):266–271.
   Web of Science ®Google Scholar
• Lanza M, Polistina GE, Imitazione P, et al. Successful intravenous immunoglobulin treatment in severe COVID-19 pneumonia. IDCases. 2020;21:e00794.
   PubMed Web of Science ®Google Scholar
• Mohtadi N, Ghaysouri A, Shirazi S, et al. Recovery of severely ill COVID-19 patients by intravenous immunoglobulin (IVIG) treatment: A case series. Virology. 2020 May 25;548: 1–5.
   PubMed Web of Science ®Google Scholar
• Xie Y, Cao S, Li Q, et al. Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID-19. J Infect. 2020. DOI:10.1016/j.jinf.2020.03.044. S0163-4453(20)30172-9.
   Web of Science ®Google Scholar
• Díez JM, Romero C, Gajardo R. Currently available intravenous immunoglobulin contains antibodies reacting against severe acute respiratory syndrome coronavirus 2 antigens. Immunotherapy. 2020;12(8):571–576.
   PubMed Web of Science ®Google Scholar
• Phelan AL. COVID-19 immunity passports and vaccination certificates: scientific, equitable, and legal challenges. Lancet. 2020;S0140-6736(20)31034–5. DOI:10.1016/S0140-6736(20)31034-5
   Web of Science ®Google Scholar
• Persad G, Emanuel EJ. The Ethics of COVID-19 immunity-based licenses (“Immunity Passports”). JAMA. 2020;323(22):2241.
   PubMed Web of Science ®Google Scholar